Mainz Biomed (NASDAQ:MYNZ – Get Free Report)’s share price was up 11.1% on Tuesday . The company traded as high as $0.41 and last traded at $0.39. Approximately 1,942,854 shares traded hands during trading, an increase of 274% from the average daily volume of 519,558 shares. The stock had previously closed at $0.35.
Mainz Biomed Trading Up 11.1 %
The firm has a market cap of $4.72 million, a P/E ratio of -0.24 and a beta of 0.15. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.91 and a current ratio of 0.97. The firm has a fifty day moving average of $0.38 and a 200-day moving average of $0.68.
About Mainz Biomed
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
Featured Articles
- Five stocks we like better than Mainz Biomed
- Transportation Stocks Investing
- 3 Small Cap Stocks That Insiders Are Buying
- Industrial Products Stocks Investing
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- How to Evaluate a Stock Before Buying
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
